Hundreds of attendees came together at the 14th Annual Market Access Summit to discuss, debate and demonstrate their industry expertise. Leading experts from the industry like AstraZeneca, Teva, Alcone and Janssen joined key regulators like PMPRB, CADTH and the pCPA. Some of the key topics of discussion were:
These discussions have helped to improve access to medicines yet again. Thank you for being a part of it. We look forward to seeing you in 2016 when we will continue the conversation with the latest developments in this fast-moving field.
Here’s what some of the attendees were saying at this year’s event
“Good update of new developments”
Cheryl Cann, Boehringer Ingelheim
“Great Day 1 program!”
Maya Daher, Janssen Inc
Ashley Metz has been the Director of Pharmaceutical Policy and Appropriateness with the Government of Saskatchewan since November 2014.
Ashley previously spent five years in Saskatchewan’s Executive Council where she supported the creation of Canada’s Premiers’ Health Care Innovation Working Group (HCIWG). While Saskatchewan was the co-chair of the HCIWG, Ashley was involved in the establishment of the pan-Canadian Pharmaceutical Alliance as well as the Generic Pricing Framework.
During her time in the Saskatchewan Public Service Ashley has held positions in Labour Market Development as well as other roles within the Ministry of Health.
Ashley holds a Masters of Political Science from the University of Saskatchewan.
A career public servant, Doug has a background in international trade law, intellectual property policy, pharmaceutical industry issues and competition law enforcement.
Doug attended McGill University, the University of New Brunswick and l'Université de Moncton. He graduated law school in 1997 and was called to the Ontario Bar in 1999 after a clerkship with the Honourable Marc Noël of the Federal Court of Appeal.
In 2000, Doug was hired by Industry Canada to assist in the case management of two WTO-based legal challenges to Canada’s pharmaceutical patent regime brought by the US and EU. In 2006, Doug became the Director of the Patent and Trademark Policy Directorate at Industry Canada, where he led a number of legislative and regulatory initiatives under the Patent Act and Trademarks Act, including the development of Canada’s Access to Medicines Regime (CAMR) and pharmaceutical patent litigation reform. In 2009, Doug joined the Competition Bureau as Assistant Deputy Commissioner, Civil Matters Branch, where he was responsible for a number of high profile prosecutions under the Competition Act.
Doug became Executive Director of the PMPRB on October 28, 2013.
Dr. Laureen Rance (BScPharm, PharmD, MSc) has over twenty years of experience working in health care, beginning as a staff pharmacist in both retail and hospital settings. After completing her Doctor of Pharmacy from the University of Toronto, she transitioned to the pharmaceutical industry. She worked as a reimbursement strategist with a focus on Health Economics and Outcomes Research supporting numerous therapeutic categories with resulting publications.
She went on to receive her Master of Science in Clinical Epidemiology from the University of Toronto and transitioned her career to work in pharmacy benefits management focused on evidence informed programs and services. She is now rounding out her private payer experience with Manulife as Director Pharmaceutical Relations
A results-driven healthcare leader with three decades of innovative achievement in building and transforming organizations. A senior executive with experience in public and private sector, multinational and start-up healthcare organizations, Jane possesses an exceptional ability to vision the healthcare system from multiple vantage points. Jane has been at the forefront of policy transformation, generating and delivering compelling solutions to complex challenges. A passionate champion for patient-centred pharmacy practice advancement and value-driven outcomes, she is a sought-after speaker, collaborator and advisor.
Peter Gove, innovation leader, health management with Green Shield Canada (GSC), has oversight for initiatives under GSC’s Change4Life™ banner. Change4Life™ is aimed at supporting Canadians to better manage their health. The initiative utilizes advanced analytics to proactively identify plan participants who are at risk of developing, or who have developed a chronic disease and to reach out to them with focused programs.
Prior to coming to GSC, Peter was responsible for the national disability management and life insurance claims program for a large Canadian life insurance company.
Mr. Gove has a master’s degree in social work and is a registered social worker. Continuing his education, he started a PhD program in Applied Health Science at the University of Waterloo. He has presented internationally in the areas of health management and disability management and was the recipient of the 2014 Vision and Values Award presented by the Canadian Life and Health Insurance Association.
Beth Molloy-Whaley is the Senior Director of Consulting for Innomar Strategies, based out of our Head Office in Oakville, Ontario. She joined the company in May 2014. Beth has 25 years of pharmaceutical industry experience. Starting her Pharma career in sales, Beth has held senior level positions in Marketing, Sales Leadership, Market Access and Commercial Excellence for companies such as Bayer, GSK, Biogen Idec, and Hoffman-LaRoche. She has worked in multiple therapeutic areas in primary care, oncology and biologics. In addition to extensive pharmaceutical industry experience, Beth owned and operated an independent consulting firm assisting companies in Canada and internationally to develop strategic plans, improve processes and develop commercial talent.
Beth oversees the consulting services offered by Innomar in the areas of business strategy, market access, health outcomes evidence generation and optimization of the patient experience.
Colin Vicente, Managing Director, holds a MSc in Health Economics from the University of Toronto, Faculty of Pharmacy. Colin has spent the last 15 years designing and implementing health economic studies, executing on price optimization plans and delivering results through successful reimbursement strategies. His innovative approaches and take charge attitude will allow him to continue to deliver high quality results for PIVINA’s clients.
Brent Fraser is CADTH Vice-President, Pharmaceutical Reviews, with responsibility for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, therapeutic class reviews, and optimal use projects, as well as drug-related Environmental Scans, Horizon Scans, and Rapid Response. Brent and his team deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies.
Brent is known as a thoughtful, listening, and collaborative leader who translates evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with strategic skills developed over many years working in the field of drug funding decisions. Brent holds an MBA from York University and a BSc. in Pharmacy from the University of Toronto. He is a member of the Ontario College of Pharmacists.